Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FQGKV
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $6,377
Award facts
- Contract value 100% obligated
- $6,376.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $6,376.64 delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by July 22, 2025. The award represents a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across military and veteran healthcare systems.
AmerisourceBergen's SPE2DX contract functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply an extensive range of medications, specialty drugs, vaccines, and medical supplies to support Defense Health Agency and other government healthcare programs worldwide. The company's demonstrated capability to meet federal procurement requirements across multiple therapeutic domains—from diabetes and neurological treatments to pain management and specialty auto-injectors—has established it as a significant player in the federal pharmaceutical supply chain. This particular delivery order for Xolair, a biologics medication used in immunology and allergic disease treatment, exemplifies the routine, high-volume pharmaceutical deliveries AmerisourceBergen executes through its prime vendor relationship with the Defense Logistics Agency.
Quick answers
Who was awarded contract SPE2DB25FQGKV?
SPE2DB25FQGKV was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on June 30, 2025.
How much is contract SPE2DB25FQGKV worth?
The government has obligated $6,377 on SPE2DB25FQGKV.
Is contract SPE2DB25FQGKV an order under another contract?
Yes. SPE2DB25FQGKV is a delivery order under SPE2DB25D3005, an indefinite delivery contract.
Was contract SPE2DB25FQGKV competed?
The extent of competition for SPE2DB25FQGKV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award